ADL Amdl,

TUSTIN, Calif., Aug. 15 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, today reported that German researchers at the Department of Gynecology and Gynecological Oncology at the University of Mainz, Germany, concluded in an abstract that AMDL's DR-70(R) test has both higher levels of sensitivity and specificity when the test is run simultaneously with CA-125, a tumor marker for the detection of ovarian carcinoma, than when CA-125 is run alone. The researchers collected blood from 100 apparently healthy females and 61 ovarian cancer patients. The cut off level for DR-70(R) was set at 1.2 ug/ml. The specificity of DR-70 at this level was 100 percent and the sensitivity was 83.6 percent. Relative to CA-125, which is considered the standard tumor marker for ovarian cancer, a cut off level of >65 U/ml was applied. The comparable sensitivity of DR-70(R) was higher by 13.1 percent, indicating that the concurrent use of DR-70(R) and CA-125 would provide a more precise correlation when monitoring ovarian cancer patients. Among gynecological malignancies, it always has been a major diagnostic problem to clearly identify ovarian carcinoma. "The combined application of both tests should be considered an improvement in correctly diagnosing ovarian cancer particularly with regards to specificity," the scientists concluded. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright